Combined detection of α-fetoprotein and free β‑human chorionic gonadotropin in screening for trisomy 21 and management of cases in the moderate risk value range

Li,Yahong; Zhang,Xiaojuan; Sun,Yun; Hong,Dongyang; Wang,Yanyun; Xu,Zhengfeng; Jiang,Tao

doi:10.3892/mco.2017.1355

October-2017 Volume 7 Issue 4

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

October-2017 Volume 7 Issue 4

Full Size Image

Article

Combined detection of α-fetoprotein and free β‑human chorionic gonadotropin in screening for trisomy 21 and management of cases in the moderate risk value range

Authors:
- Yahong Li
- Xiaojuan Zhang
- Yun Sun
- Dongyang Hong
- Yanyun Wang
- Zhengfeng Xu
- Tao Jiang
View Affiliations / Copyright

Affiliations: Center of Prenatal Diagnosis, Obstetrics and Gynecology Hospital Affiliated to Nanjing Medical University, Nanjing, Jiangsu 210004, P.R. China
Pages: 623-628
|
Published online on: July 31, 2017

https://doi.org/10.3892/mco.2017.1355
Expand metrics +

Abstract

Down syndrome is the most common cause of prenatal chromosomal abnormalities, and prenatal serum screening is an effective method for decreasing the birth prevalence of children with Down syndrome. The aim of the present study was to observe the effect of duplex screening and investigate the treatment of cases under specific conditions. The medians of free β‑human chorionic gonadotropin (HCG) and α‑fetoprotein (AFP) were calculated and compared with those embedded in the 2T software. The detection and false‑positive rates were analyzed under different conditions, and the distribution of Down syndrome cases was investigated in different risk ranges. Finally, suitable recommendations for further diagnostic investigation were provided according to the status of each individual. The medians of free β‑HCG and AFP were found to differ from the corresponding medians embedded in the 2T software (P<0.01), and on the basis of a 5% false‑positive rate, the detection rate would increase from 63.6 to 67.8% when compared with medians embedded in the 2T software, indicating we should establish our own medians of free β‑HCG and AFP. In addition, residual cases (risk value <1/300) with relevant Down syndrome indications mainly concentrated at risk values between 1/1,000 and 1/300, and partial residual screening cases were verified through diverse methods. These findings indicated that different laboratories should establish their own medians; furthermore, what is classed as moderate risk is extremely important in screening for Down syndrome and reasonable recommendations may be offered under different conditions.

View Figures

View References

1	Smith M and Visootsak J: Noninvasive screening tools for Down syndrome: A review. Int J Womens Health. 5:125–131. 2013.PubMed/NCBI
2	Avent ND: Maternal plasma biomarkers for down syndrome: Present and future. Drugs Today (Barc). 49:145–152. 2013. View Article : Google Scholar : PubMed/NCBI
3	Alldred SK, Deeks JJ, Guo B, Neilson JP and Alfirevic Z: Second trimester serum tests for Down's Syndrome screening. Cochrane Database Syst Rev. 13:CD0099252012.
4	Androutsopoulos G, Gkogkos P and Decavalas G: Mid-trimester maternal serum HCG and alpha fetal protein levels: Clinical significance and prediction of adverse pregnancy outcome. Int J Endocrinol Metab. 11:102–106. 2013. View Article : Google Scholar : PubMed/NCBI
5	Extermann P, Bischof P, Marguerat P and Mermillod B: Second-trimester maternal serum screening for Down's syndrome: Free beta-human chorionic gonadotrophin (HCG) and alpha-fetoprotein, with or without unconjugated oestriol, compared with total HCG, alpha-fetoprotein and unconjugated oestriol. Hum Reprod. 13:220–223. 1998. View Article : Google Scholar : PubMed/NCBI
6	Shaw SW, Hsu JJ, Lee CN, Hsiao CH, Chen CP, Hsieh TT and Cheng PJ: First- and second-trimester Down syndrome screening: Current strategies and clinical guidelines. Taiwan J Obstet Gynecol. 47:157–162. 2008. View Article : Google Scholar : PubMed/NCBI
7	Sayin NC, Canda MT, Ahmet N, Arda S, Süt N and Varol FG: The association of triple-marker test results with adverse pregnancy outcomes in low-risk pregnancies with healthy newborns. Arch Gynecol Obstet. 277:47–53. 2008. View Article : Google Scholar : PubMed/NCBI
8	Wang YY, Luo J, Zhu MW, Liu LN and Ma X: Second-trimester double or triple screening for Down syndrome: A comparison of Chinese and Caucasian populations. Int J Gynaecol Obstet. 94:67–72. 2006. View Article : Google Scholar : PubMed/NCBI
9	Sifakis S, Papantoniou N, Kappou D and Antsaklis A: Noninvasive prenatal diagnosis of Down syndrome: Current knowledge and novel insights. J Perinat Med. 40:319–327. 2012. View Article : Google Scholar : PubMed/NCBI
10	Nicolaides KH, Syngelaki A, Gil M, Atanasova V and Markova D: Validation of targeted sequencing of single-nucleotide polymorphisms for non-invasive prenatal detection of aneuploidy of chromosomes 13, 18, 21, X and Y. Prenat Diagn. 33:575–579. 2013. View Article : Google Scholar : PubMed/NCBI
11	Shaw SW, Chen CP and Cheng PJ: From Down syndrome screening to noninvasive prenatal testing: 20 years' experience in Taiwan. Taiwan J Obstet Gynecol. 52:470–474. 2013. View Article : Google Scholar : PubMed/NCBI
12	Ehrich M, Deciu C, Zwiefelhofer T, Tynan JA, Cagasan L, Tim R, Lu V, McCullough R, McCarthy E, Nygren AO, et al: Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood: A study in a clinical setting. Am J Obstet Gynecol. 204:205.e1–11. 2011. View Article : Google Scholar
13	Baffero GM, Somigliana E, Crovetto F, Paffoni A, Persico N, Guerneri S, Lalatta F, Fogliani R and Fedele L: Confined placental mosaicism at chorionic villous sampling: Risk factors and pregnancy outcome. Prenat Diagn. 32:1102–1108. 2012. View Article : Google Scholar : PubMed/NCBI
14	Bamberg C, Fotopoulou C, Thiem D, Roehr CC, Dudenhausen JW and Kalache KD: Correlation of midtrimester amniotic fluid cytokine concentrations with adverse pregnancy outcome in terms of spontaneous abortion, preterm birth and preeclampsia. J Matern Fetal Neonatal Med. 25:812–817. 2012. View Article : Google Scholar : PubMed/NCBI
15	Guedj F and Bianchi DW: Noninvasive prenatal testing creates an opportunity for antenatal treatment of Down syndrome. Prenat Diagn. 33:614–618. 2013. View Article : Google Scholar : PubMed/NCBI
16	Van Opstal D and Srebniak MI: Cytogenetic confirmation of a positive NIPT result: Evidence-based choice between chorionic villus sampling and amniocentesis depending on chromosome aberration. Expert Rev Mol Diagn. 16:513–520. 2016. View Article : Google Scholar : PubMed/NCBI
17	Yu DY, Fu P, Zhang ZH, Wang F, Han MY, Ren HY, Zhao W, Zhang K, Li S and Jiang N: Evaluation of Down's syndrome screening methods using maternal serum biochemistry in the second trimester pregnancy. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 28:332–335. 2011.(In Chinese). PubMed/NCBI
18	Lim JH, Park SY and Ryu HM: Non-invasive prenatal diagnosis of fetal trisomy 21 using cell-free fetal DNA in maternal blood. Obstet Gynecol Sci. 56:58–66. 2013. View Article : Google Scholar : PubMed/NCBI